Compare · ABT vs SXTC
ABT vs SXTC
Side-by-side comparison of Abbott Laboratories (ABT) and China SXT Pharmaceuticals Inc. (SXTC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and SXTC operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $155.32B, about 2309.1x SXTC ($67.3M).
- Over the past year, ABT is down 33.6% and SXTC is down 99.4% - ABT leads by 65.8 points.
- ABT has been more active in the news (6 items in the past 4 weeks vs 2 for SXTC).
- ABT has more recent analyst coverage (25 ratings vs 0 for SXTC).
- Company
- Abbott Laboratories
- China SXT Pharmaceuticals Inc.
- Price
- $89.73+0.71%
- $1.80+2.56%
- Market cap
- $155.32B
- $67.3M
- 1M return
- +6.28%
- +6.80%
- 1Y return
- -33.60%
- -99.38%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 6
- 2
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
China SXT Pharmaceuticals Inc.
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine piece tablets (TCMP) in China. It offers advanced, fine, and regular TCMP products, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. The company provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. As of July 31, 2021, its end-customer base includes 70 pharmaceutical companies, 12 chain pharmacies, and 59 hospitals in 10 provinces and municipalities in China, including Jiangsu, Hubei, Shandong, Guangdong, Liaoning, Anhui, Henan, Jiangxi, Heilongjiang, and Hainan. The company was founded in 2005 and is based in Taizhou, China.
Latest ABT
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
Latest SXTC
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- SEC Form 424B5 filed by China SXT Pharmaceuticals Inc.
- SEC Form 6-K filed by China SXT Pharmaceuticals Inc.
- SEC Form 3 filed by new insider Pan Xiaodong Sean
- SEC Form 3 filed by new insider Liu Tong Tony
- SEC Form 3 filed by new insider Ji Xiaodong
- New insider Zhou Feng Felix claimed ownership of 4 units of Class B Ordinary Shares (SEC Form 3)
- SEC Form 3 filed by new insider Chee Yong Lip
- SEC Form 3 filed by new insider Simon Lim Sze Beng
- SEC Form 3 filed by new insider Zheng Jun